How to Trade XBI, the SPDR S&P Biotech ETF, on Hyperliquid

What XBI Actually Holds

XBI is State Street's SPDR S&P Biotech ETF, listed on NYSE Arca since January 31, 2006. It holds 155 positions, charges a 0.35% gross expense ratio, and ran $12.08 billion in net assets at a NAV of $168.32 as of August 26, 2026.

The structural detail that defines it: XBI tracks the S&P Biotechnology Select Industry Index, and S&P's Select Industry methodology is *modified equal weight*, rebalanced quarterly in March, June, September and December. Every constituent starts the quarter at roughly the same weight, subject to a cap, regardless of market cap. A clinical-stage company with no product revenue gets close to the same sleeve as a commercial large cap.

That is not a cosmetic difference. Cap-weighted biotech funds concentrate in the handful of profitable large caps and end up behaving like slow pharma proxies. XBI behaves like the small- and mid-cap biotech tape. As of August 26, 2026 its largest holding was Moderna at 2.89%, followed by Twist Bioscience at 1.97%, Apogee Therapeutics at 1.45%, Kymera Therapeutics at 1.43% and Praxis Precision Medicines at 1.39%. Nothing in the fund is load-bearing on its own — and Moderna only sits on top because it jumped roughly 177% on the August 19 vaccine readout and has not been rebalanced back down yet.

The practical read: trade XBI when you have a view on biotech as a risk asset — rates, FDA posture, deal flow, whether the financing window is open. Do not trade it as a proxy for any single drug.

Why Biotech Is Bid Into Late 2026

The fund's NAV returned 20.68% year to date and 72.46% over one year through July 31, 2026, per State Street's own performance disclosure. The 52-week range runs $89.33 to $169.89. Zoom out and the move is bigger: XBI has advanced roughly 155% from an April 2025 swing low of $66.66, according to FXEmpire's technical review.

Three things are carrying it.

Deal flow. Biotech M&A reached $106 billion across 201 transactions by early June 2026, the sector's strongest pace since before the pandemic. Equal weighting is the entire point here — takeouts land on small and mid caps, and XBI holds those at weights that actually register.

The patent cliff. Large pharma is staring at roughly $170 billion of revenue exposed to patent expiry. Buying pipeline is the only fast fix, which puts a structural bid under clinical-stage assets independent of the macro cycle.

Clinical proof points. On August 19, 2026, Merck and Moderna reported that intismeran autogene plus Keytruda succeeded in the first randomized Phase 3 trial of a personalized mRNA cancer vaccine, in resected melanoma. Readouts like that reprice the sector's option value, not just the two companies named on the press release.

The counterweight is the same one it has always been. This is a rate-sensitive, long-duration, cash-burning sector. It went from a February 2021 high near $174.79 to that $66.66 low. The recovery is real; so was the drawdown, and the mechanism that produced it has not been repealed.

The HIP-3 Contract, Line by Line

The XBI perp is not a Hyperliquid product. It is deployed under HIP-3, builder-deployed perpetuals, which went live on mainnet in October 2025 and lets any team staking 500,000 HYPE run its own perp DEX on HyperCore — its own listings, margin parameters, oracle and risk limits. Validators can slash that stake by stake-weighted vote if a market is operated maliciously. That is the trust boundary you are accepting.

The deployer is trade[XYZ], which the ticker names directly: xyz:XBI. Per [trade[XYZ]'s contract specification](https://docs.trade.xyz/consolidated-resources/specification-index), the contract references 1 share of XBI, is quoted in USD, is margined and settled in USDC, and caps leverage at 10x. It trades 24/5, Sunday 8:00 PM ET to Friday 8:00 PM ET, and observes U.S. equity holidays.

Pricing is the part worth actually reading. The oracle uses externally derived fair prices from institutional venues and data providers whenever the underlying is trading. When those inputs go away — overnight, holidays — it falls back to an internal continuous-time EMA driven by the impact bid and ask on Hyperliquid's own book, with a 30-minute time constant and per-update weight capped near 9.5%. When external data resumes, it reverts to the external price on the next tick.

Funding is charged hourly against that oracle: perp persistently above oracle, longs pay shorts; persistently below, shorts pay longs. Corporate actions are absorbed into the reference price — splits adjust it proportionally with your position size scaling to match, and the underlying's forward dividend yield enters through the cost-of-carry conversion from futures to spot. You never hold a share, never receive a distribution, and never touch creation/redemption. You hold USDC-margined exposure to a number.

Where This Trade Breaks

Liquidity is the binding constraint right now. The XBI perp turned over $16,261 in the last 24 hours at a mark near $168.40 — under a hundred share-equivalents. That is a market a single trader can move. Use limit orders, expect the book to thin out fast on either side of the touch, and size to what you can exit rather than what your margin permits.

The weekly close is a genuine gap. From Friday 8:00 PM ET to Sunday 8:00 PM ET there is no market. Biotech news does not respect that window: FDA decisions, conference data drops and deal announcements land on weekends routinely. A leveraged position carried through Friday night is one you cannot manage until Sunday.

Overnight marks come from your own order book. Between the NYSE Arca close and the next session, the oracle runs on Hyperliquid's impact bid/ask rather than XBI's last print. In a thin book that EMA can drift from fair value, and it is marking both your PnL and your liquidation price. The 30-minute time constant and per-update cap limit how fast it moves, which cuts both ways — it damps manipulation and it damps legitimate repricing.

10x on this underlying is aggressive. XBI's realized range is wide by construction: a basket of largely pre-revenue companies whose value is a discounted probability of approval. It has traded $174.79 down to $66.66. At 10x, a single 8% sector day against you takes most of your margin.

Levels worth knowing. The February 2021 all-time high at $174.79 is the resistance the tape is testing, with the recent trend high at $169.89 and the last swing low at $161.49, per FXEmpire's August 25 read. A clean break of the 2021 high resolves a five-year base; a rejection there builds the handle instead.

Equal weight does not diversify away policy. Single-name binary risk is genuinely muted when the largest holding is 2.89% and the average is under 1%. Sector-wide risk is not muted at all. Drug-pricing policy, an FDA leadership change, or a rate repricing hits all 155 names on the same day — and that is the risk you are actually taking when you lever this contract.